APNS Receives Patent for Alzheimer's Test Technology

A U.S. patent has been issued covering certain aspects of Applied NeuroSolutions' (APNS) Alzheimer's blood diagnostic technology.

Currently there is no FDA-approved biologic test for Alzheimer's disease (AD). The company believes the market potential for biologic tests to diagnose AD is quite large and will depend upon several factors, including the accuracy and cost of the test, its ease of use, how early it is able to predict the disease, and the development of more effective drugs to slow down the progression of AD.

"The company is pursuing development of second generation tests for diagnosing Alzheimer's disease, and the patent recently awarded supports one of the key methodologies we are focused on," said John DeBernardis, APNS president and CEO.